Artiva grants director Sorg 16,250 stock options

A director of Artiva Biotherapeutics, Inc. received a new stock option grant that vests in 2027 and provides rights to purchase 16,250 shares at $10.42.

Available on EDGAR 09/14/2026 - 04:05 PM EDT Accepted by SEC EDGAR 09/14/2026 - 04:04 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Artiva Biotherapeutics, Inc. (ARTV) reported that director Elaine K. Sorg received a stock option grant for 16,250 shares of common stock on September 10, 2026. The option has an exercise price of $10.42 per share, expires on September 9, 2036, and will vest in full on the earlier of September 10, 2027, or the company’s 2027 annual stockholder meeting. After this grant, she holds options for 16,250 shares directly, and no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Grant/Award: 16,250 shares

Grant/Award 1 txn

Insider Sorg Elaine K.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy) F1	16,250	$0.00	$0.00

Holdings After Transaction: Director Stock Option (Right to Buy) — 16,250 contracts (Direct)

Holdings Before and After: Director Stock Option (Right to Buy), 0 to 16,250 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting.

Key Figures

Option shares granted: 16,250 shares Exercise price: $10.42 per share Expiration date: September 9, 2036 +3 more

6 metrics

Option shares granted 16,250 shares Director stock option grant on September 10, 2026

Exercise price $10.42 per share Exercise price of director stock options granted September 10, 2026

Expiration date September 9, 2036 Expiration of the granted director stock options

Vesting outside date September 10, 2027 Latest date when options vest, or earlier 2027 annual meeting date

Options held after grant 16,250 shares Director’s option holdings following the reported grant

Grant price at transaction $0.00 per option No cash price paid at the time of the option grant

Key Terms

stock option, exercise price, vesting, annual stockholder meeting

4 terms

stock option financial

"director received a stock option grant for 16,250 shares of common stock"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"The option has an exercise price of $10.42 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"will vest in full on the earlier of September 10, 2027, or the company’s 2027 annual stockholder meeting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual stockholder meeting regulatory

"earlier of September 10, 2027, or the company’s 2027 annual stockholder meeting"

An annual stockholder meeting is a yearly gathering where a company's owners (shareholders) receive updates on performance, vote on key issues like board members, executive pay and major corporate plans, and ask questions of management. Think of it as a company town hall where choices about oversight and direction are decided; outcomes can affect management accountability, corporate strategy and ultimately the value and risks of investors’ shares.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ARTV report for director Elaine K. Sorg?

Elaine K. Sorg received a stock option grant for 16,250 shares of Artiva Biotherapeutics, Inc. common stock on September 10, 2026, as director compensation.

What is the exercise price of the new ARTV stock options?

The granted options have an exercise price of $10.42 per share, allowing the director to buy Artiva Biotherapeutics, Inc. common stock at that price once vested.

When do the newly granted ARTV options vest?

The options will vest in full on the earlier of September 10, 2027, or the date of Artiva Biotherapeutics, Inc.’s 2027 annual stockholder meeting, according to the grant terms.

How many ARTV option shares does the director hold after this grant?

After the transaction, the director holds options covering 16,250 shares of Artiva Biotherapeutics, Inc. common stock, all held as a direct ownership position reported in this grant.

Was the ARTV option grant made under a Rule 10b5-1 trading plan?

No. The report indicates that no Rule 10b5-1 trading plan applies to this option grant to the Artiva Biotherapeutics, Inc. director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sorg Elaine K.

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$10.42	09/10/2026		A		16,250		(1)	09/09/2036	Common Stock	16,250	$0	16,250	D

Explanation of Responses:

1. The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting.

	/s/ Jennifer Bush, Attorney-in-Fact	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)